Impact of genotypic susceptibility score on cART outcomes during primary HIV infection: Journal of Medical Virology

A Giacomelli, M Fabbiani, I De Benedetto, S Nozza, E Focà, BM Celesia, G Marchetti, C Mussini, A Antinori, G d’Ettorre, G Madeddu, A Bandera, A Muscatello, S Rusconi

Research output: Contribution to journalArticlepeer-review

Abstract

To assess the impact of genotypic susceptibility score (GSS) on combined antiretroviral therapy (cART) outcomes during primary HIV infection (PHI) we retrospectively enrolled patients with PHI diagnosed between 2008 and 2015 at 9/24 Italian Network ACuTe HIV InfectiON centers. One hundred-seventy-six patients were enrolled. Of these, 55 (32.9%) patients started with more than three drugs and 11 (7.2%) started with a GSS <3. Regimen's GSS (per 1 point increase) (adjusted odds ratio [aOR], 4.82; 95% confidence interval [CI], 1.62-14.28; P =.005) and baseline HIV-RNA (per 1 log10 increase) (aOR, 2.02; 95% CI, 1.09-3.73; P =.025) resulted associated with early cART initiation. In conclusion, regimen's GSS resulted to be associated to the time to cART initiation during PHI. © 2019 Wiley Periodicals, Inc.
Original languageEnglish
Pages (from-to)1891-1895
Number of pages5
JournalJournal of Medical Virology
Volume91
Issue number10
DOIs
Publication statusPublished - 2019

Fingerprint Dive into the research topics of 'Impact of genotypic susceptibility score on cART outcomes during primary HIV infection: Journal of Medical Virology'. Together they form a unique fingerprint.

Cite this